Alnylam Pharmaceuticals, Inc.
Nasdaq 100
$159.89
+1.20%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Net profit margin is 8.5%.
- Current assets comfortably cover current liabilities (current ratio 2.76).
!Watch-points
- Return on equity is on the lower side at 8.7%.
- Return on capital employed is on the lower side at 7.7%.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreGrey zone
2.91
This middle range was less conclusive in Altman’s study — neither clearly safe nor clearly distressed.
Piotroski F-ScoreModerate
5 / 7
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 7 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap$21.42B
Current Price$ 159.89
High / Low$ 479.79 / 156.00
Stock P/E8.075253
Book Value$ 26.11
Dividend Yield0%
ROCE7.68%
ROE8.71%
Current Ratio2.76
P/B Ratio5.9394503
EPS$ 2.33
PAT Margin8.45%
Cash PAT$369.41M
ICR1.99